Aurobindo Pharma gains after reporting strong Q4 results

Aurobindo Pharma rose 1.58% to Rs 766.35 at 10:20 IST on BSE after consolidated net profit rose 39.38% to Rs 562.85 crore on 18.88% growth in total income to Rs 3767.34 crore in Q4 March 2016 over Q4 March 2015.

The result was announced after market hours yesterday, 30 May 2016.

Meanwhile, the BSE Sensex was down 81.42 points, or 0.27%, to 26,653.77.

On BSE, so far 1.14 lakh shares were traded in the counter, compared with an average volume of 1.71 lakh shares in the past one quarter. The stock hit a high of Rs 786.50 and a low of Rs 761.10 so far during the day. The stock hit a record high of Rs 891.50 on 30 December 2015. The stock hit a 52-week low of Rs 582 on 25 February 2016.

The large-cap company has an equity capital of Rs 58.52 crore. Face value per share is Re 1.

Aurobindo Pharma's consolidated earnings before interest, taxes, depreciation and amortization (EBITDA) margin rose to 23.5% in Q4 March 2016 compared with 20.7% in Q4 March 2015. Consolidated operating profit (EBIDTA) before forex rose 34.5% to Rs 882 crore in Q4 March 2016 over Q4 March 2015.

Aurobindo Pharma's Managing Director N. Govindarajan said that the company continues its growth journey with higher number of ANDA approvals, new launches and better integration of acquired businesses. With growth coming from all business verticals, focus remains on new launches in US and improved cost efficiencies in EU, he said. In addition, Aurobindo continues to work on new businesses and differentiated technology platforms which will drive its future growth, he added.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals, anti-allergies and anti-diabetics, supported by an outstanding R&D set-up. The company is marketing these products globally, in over 150 countries.

Powered by Capital Market - Live News